Stereotactic brachytherapy using iodine 125 seeds for the treatment of primary and recurrent anaplastic glioma WHO° III

Stereotactic brachytherapy using iodine 125 seeds for the treatment of primary and recurrent anaplastic glioma WHO° III

The current study analyzed the outcome after stereotactic brachytherapy (SBT) using iodine-125 seeds in anaplastic astrocytoma, oligoastrocytoma or oligodendroglioma not suitable for resection. Out of 223 patients harbouring a malignant glioma treated according to a prospective protocol, 172 patient...

Full description

Saved in:
Bibliographic Details
Published in:Journal of neuro-oncology Vol. 130; no. 1; pp. 123 - 131
Main Authors: Suchorska, B., Hamisch, C., Treuer, H., Mahnkopf, K., Lehrke, R. E., Kocher, M., Ruge, M. I., Voges, J.
Format: Journal Article
Language:English
Published: New York Springer US 01-10-2016
Subjects:
Adult
Brachytherapy - methods
Clinical Study
Disease-Free Survival
Female
Follow-Up Studies
Glioma - radiotherapy
Humans
Iodine Radioisotopes - therapeutic use
Male
Medicine
Medicine & Public Health
Middle Aged
Neoplasm Recurrence, Local - radiotherapy
Neurology
Oncology
Retrospective Studies
Statistics, Nonparametric
Treatment Outcome
World Health Organization
SBT
Anaplastic glioma
Outcome
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The current study analyzed the outcome after stereotactic brachytherapy (SBT) using iodine-125 seeds in anaplastic astrocytoma, oligoastrocytoma or oligodendroglioma not suitable for resection. Out of 223 patients harbouring a malignant glioma treated according to a prospective protocol, 172 patients were selected who received SBT to treat a WHO grade III de-novo/residual tumor (n = 99) or a tumor recurrence after multimodal treatment (n = 73). We assessed progression free survival (PFS), overall survival (OS), radiological and clinical outcome and determined prognostic factors using univariate and multivariate regression analyses. The median follow-up time was 38 months. Median OS and median PFS was 28.9 and 21.4 months in the de-novo group vs. 49.4 and 32.6 months in the recurrence group. Recurrent tumors had more frequently (p = 0.01) an oligodendroglial-component compared to de novo tumors. According to cohort-specific univariate analyses KPS at SBT had a significant (p = 0.008) impact on OS in the de-novo group. In the recurrence group, (Cox regression analysis) OS was significantly associated with histology subtype (oligoastro-/oligodendroglioma vs. astrocytoma, p = 0.043). Transient and permanent morbidity (~1 %) was low. For patients unable to undergo surgery due to eloquent tumour location or reduced general condition SBT is an effective treatment option, which does not foreclose additional therapeutic interventions.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:0167-594X
1573-7373
DOI:10.1007/s11060-016-2214-x